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ABSTRACT 
 
We conducted a 15-year retrospective cohort study to determine the prevalence of 
restrictive lung disease prior to allogeneic hematopoietic cell transplant (HCT), and to 
assess whether this was a risk factor for poor outcomes. 2545 patients were eligible for 
the analysis.  Restrictive lung disease was defined as a total lung capacity (TLC) <80% 
of predicted normal.  Chest x-rays and /or computed tomography scans were reviewed 
for all restricted patients to determine whether lung parenchymal abnormalities were 
unlikely or highly likely to cause restriction.  Multivariate Cox-proportional hazard and 
sensitivity analyses were performed to assess the relationship between restriction and 
early respiratory failure and nonrelapse mortality.  Restrictive lung disease was present 
in 194 subjects (7.6%) prior to transplantation.  Among these cases, radiographically 
apparent abnormalities were unlikely to be the cause of the restriction in 149 (77%) 
subjects.  In unadjusted and adjusted analyses, the presence of pulmonary restriction 
was significantly associated with a 2-fold increase in risk for early respiratory failure and 
nonrelapse mortality, suggesting that these outcomes occurring in the absence of 
radiographically apparent abnormalities may be related to respiratory muscle weakness.  
These findings suggest that pulmonary restriction should be considered as a risk factor 
for poor outcomes after transplant. 
 
Word count: 198 
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INTRODUCTION 
Pulmonary function tests (PFTs) are routinely performed before allogeneic 
hematopoietic cell transplantation (HCT) as a screen for underlying respiratory 
abnormalities and to provide baseline lung function measurements for comparison when 
transplant-related pulmonary complications are suspected [1].  Several studies 
examining the predictive value of pretransplant PFTs for post-transplant complications 
have demonstrated that impaired lung function before transplant increases the risk for 
post-transplant pulmonary complications and mortality [2-14].  However, the majority of 
these previous studies primarily focused on the one-second forced expiratory volume 
(FEV1) [2, 12, 14] and the carbon monoxide (CO) diffusion capacity (DLCO) [10-12, 14] 
as a surrogate measure of pulmonary gas exchange, or the effect of specific physiologic 
patterns such as the effect of pretransplant airflow obstruction on post-transplant 
outcomes [3, 4, 9, 12] .  Although a few studies have evaluated the relationship between 
pretransplant pulmonary restriction and post-transplant outcomes [2, 12, 15], the 
prevalence of restrictive lung disease prior to allogeneic HCT and their influence on 
transplant outcomes is not well described. 
There are multiple factors that can result in a restrictive pattern on pulmonary 
function testing prior to stem cell transplantation.  These include advanced intrathoracic 
malignant lesions, spinal cord compression, prior treatments such as chemotherapy, 
thoracic surgery, thoracic radiation, or prior chronic respiratory disease or infection, 
and/or myopathies/deconditioning resulting in respiratory muscle weakness [1].  In a 
recent study, we found evidence that a reduced total lung capacity (TLC) prior to 
allogeneic HCT, which defines pulmonary restriction, may influence post-transplant 
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outcomes [8].  These preliminary data and the current gap in knowledge regarding 
restrictive pulmonary processes and allogeneic HCT outcomes prompted us to conduct 
a 15-year retrospective cohort study to determine the prevalence of restrictive lung 
disease prior to allogeneic HCT, and assess whether this is a pretransplant risk factor 
for two major transplantation outcomes: early respiratory failure and nonrelapse 
mortality. 
 
METHODS 
Patient Selection 
All patients who had their first allogeneic HCT at Fred Hutchinson Cancer 
Research Center/Seattle Cancer Care Alliance (the “Center”) between July 6, 1992, and 
July 6, 2005, were eligible for this analysis (n = 2847).  Patients who were younger than 
15 years (n = 170), or without a pretransplant assessment of pulmonary static lung 
volumes (n = 132) were excluded.  A total of 2545 patients were included in the final 
analyses.  
 
Clinical Data 
All clinical data were prospectively collected and retrospectively reviewed.  The 
patient's underlying disease state was categorized as low, intermediate, or high risk as 
previously described [8, 16].  Donor match status was determined according to donor–
recipient ABO compatibility and HLA-A, HLA-B, and HLA-DR status.  Stem cell sources 
were classified as bone marrow, peripheral blood stem cell, or other, which included 
cord blood, or a combination of bone marrow and peripheral blood stem cell. 
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Conditioning regimens were classified as reduced intensity or myeloablative.  Patients 
in the myeloablative conditioning group included patients that received either a TBI- or 
non–TBI-based regimen.  Patients in the reduced intensity conditioning group received 
2 Gy of total body irradiation (TBI).  Body mass index (BMI) was calculated using weight 
and height and categorized as underweight (BMI<18.5), normal weight (BMI 18.5-24.9), 
overweight (BMI 25.0-29.9) and obese (BMI >30.0) [17]. 
 
Pulmonary function testing 
According to standard transplant protocol at our Center, all patients underwent 
pulmonary function testing prior to transplantation when possible.  The PFT obtained 
prior to and closest to the time of transplantation was used in the analysis.  Among 
patients who received a bronchodilator challenge, the prebronchodilator values were 
used in this analysis.  All PFTs were performed at our Center according to the American 
Thoracic Society (ATS) guidelines [18] using the Sensormedics 2100 (Sensormedics 
Co., Yorba Linda, CA) from July 1991 to August 1999, and the Sensormedics V-Max 22 
with Autobox 6200 (Sensormedics Co.) from September 1999 to July 2005.  Published 
equations for adults were used to determine predicted values of FEV1, FVC, total lung 
capacity (TLC), residual volume (RV), and diffusing capacity of carbon monoxide 
(DLCO)[18-20].  All diffusing capacity of carbon monoxide (DLCO) measurements were 
corrected for the hemoglobin measurement obtained closest to the time the diffusion 
capacity was measured, but not alveolar volume [21].   
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Chest imaging 
Chest imaging data was reviewed for all patients determined to have 
pretransplant restrictive lung disease by PFT.  Data were obtained by reviewing 
radiograph and chests computed tomography (CT) reports when available, and from 
reviewing clinical notes when imaging reports were not available.  Imaging was obtained 
within 30 days before or after stem cell transplantation in most patients (96%).  When 
both chest x-ray and chest CT results were available within the same time window, CT 
results were used preferentially.  All reports were independently and collectively 
reviewed by three pulmonologists and classified as having a high or low probability that 
parenchymal lung disease or chest wall deformities were contributing significantly to the 
restrictive lung disease.  Nodules, lobar infiltrates, cavities less than 4 cm, and small 
effusions were classified as low probability.  Evidence of thoracic surgery, elevated 
diaphragm, diffuse interstitial lung disease, pulmonary fibrosis, central masses, and 
moderate to severe pleural effusions were classified as high probability. 
 
Restrictive pulmonary disease definitions 
 Restrictive lung disease was defined according to ATS/European Respiratory 
Society (ERS) criteria, defined as a TLC<80% [20, 22].  In order to examine whether 
respiratory muscle weakness may be associated with the outcomes, we performed a 
sensitivity analysis using two additional definitions of restrictive lung disease.  The first 
definition required both TLC<80% and a FEV1/FVC ratio >0.7.  The second alternative 
definition required the same, and also required a low probability chest image, one that 
provided no evidence for a parenchymal explanation for a restrictive pattern. 
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Outcome definitions 
Patients were defined as having developed early respiratory failure if they 
required >24h hours of mechanical ventilation for a nonelective reason within the first 
120 days after transplantation.  Nonrelapse mortality was defined as mortality that 
occurred in patients who did not experience relapse of their underlying malignancy 
within the follow-up period.   
 
Statistical methods 
All statistical analyses were performed using SPSS 15.0 for Windows® (SPSS 
Inc. Chicago, Illinois) and Stata/IC 10.0 for Windows® (StataCorp LP College Station, 
Texas).  Two sided p-values < 0.05 were considered statistically significant. Diagnosis, 
disease status, and disease risk were evaluated as categorical variables.  Pulmonary 
function parameters were evaluated as both continuous and categorical variables. Body 
mass index was considered as a categorical and continuous variable.  Pearson χ2 test 
and one-way analysis of variance were used to compare categorical and continuous 
variables, respectively.  To evaluate if respiratory muscle weakness might be 
associated with worse outcomes, we performed a sensitivity analysis using three 
successively more stringent definitions for a restrictive pattern that is likely caused by 
respiratory muscle weakness.  Cox proportional hazards models were used to assess 
the relationship between pulmonary restriction and the outcomes of interest.  Patients 
who developed disease relapse were censored at the time of relapse for the nonrelapse 
mortality analysis.  To account for potential changes in clinical practice over time, we 
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considered the year of transplant as a categorical variable in the analysis.  The 
incidence of developing early respiratory failure and nonrelapse mortality according to 
lung function parameters were plotted using cumulative incidence curves, with disease 
relapse treated as a competing event for nonrelapse mortality and all cause mortality 
treated as a competing event for respiratory failure.  Cumulative incidence curves were 
compared using the methods of Gray [25]. 
 
RESULTS 
Clinical characteristics and baseline lung function.  
The pretransplant clinical characteristics of all patients are summarized in Table 
1.  The mean (± standard deviation) number of days between PFTs and transplantation 
was 24 ± 9 days.  Restrictive lung disease, defined by TLC <80%, was present in 194 
(7.6%) patients (Table 2).  The presence of restrictive lung disease increased as 
disease risk increased (p < 0.001; Table 3).  Four percent of low risk patients had 
restrictive lung disease.  This increased to 7% and 12% for patients with intermediate 
and high risk diseases, respectively. One hundred and seven chest CXR and 81 chest 
CTs were reviewed for the 194 patients with a restrictive pattern.  Six patients did not 
have any radiographic images available for review.  The majority of patients with a TLC 
< 80% had normal or near normal chest radiographic studies (n = 149; 77%) and were 
categorized as having a “low likelihood” of having parenchymal lung disease or a chest 
wall deformity as a cause of the pulmonary restriction.  The remainder of patients with a 
TLC < 80% (n = 39; 20%) had prior thoracic surgery or radiographic evidence of 
mediastinal, lung or pleural abnormalities and were classified as having a “high 
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likelihood” that parenchymal lung disease or chest wall deformities were a significant 
cause of the abnormal TLC.  Patients with the most severely decreased TLC were more 
likely to have abnormal chest imaging (31% vs. 5%, p < 0.001).   
Among pretransplant characteristics, only disease diagnosis and stage were 
significantly associated with a TLC<80% (Table 3).  Although the majority of the patients 
were in the highest TLC category, a larger percentage of the patients with Hodgkin’s 
disease had a pretransplant TLC in the lower categories (p < 0.001).  Similarly, there 
was also a significant association between the baseline TLC and disease status at 
transplant (p < 0.001).  To facilitate further analysis, we integrated the pretransplant 
diagnosis and disease status into a composite variable, disease risk, and confirmed the 
association with pretransplant TLC (Table 3).  Since physiologic deconditioning or 
pulmonary injury from significant pre-treatment can result in a restrictive pattern and 
influence the risk of developing the outcomes, disease risk represents a potential 
confounding variable.  Due to the low number of patients in each TLC category below 
80%, we also dichotomized the TLC categories into ≥80% versus <80% for the 
remaining analyses. 
 
Pretransplant restrictive lung disease and early respiratory failure  
Pretransplant restrictive lung disease was significantly associated with a higher 
risk for early respiratory failure (hazard ratio [HR] 2.22, 95% confidence interval [CI] 
1.60-3.07, p<0.001) (Table 4).  Cumulative incidence of early respiratory failure was 
significantly different between subjects with and without pretransplant TLC < 80% (p < 
0.0001, Figure 1A).  In an attempt to isolate the effect of respiratory muscle weakness 
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we repeated this analysis using progressively stringent criteria for restrictive lung 
disease.  When restrictive lung disease was defined as both a TLC<80% and FEV1/FVC 
ratio>0.7, it remained significantly associated with a two-fold increase in risk for early 
respiratory failure (HR 2.19, 95% CI 1.57-3.06, p < 0.001).  Using these criteria for 
pulmonary restriction, cumulative incidence of early respiratory failure remained 
significantly different between subjects with and without pretransplant pulmonary 
restriction (p < 0.0001, Figure 1B).  The third analysis required a TLC<80%, FEV1/FVC 
ratio >0.7, and a low probability chest radiograph.  Although attenuated slightly, a 
restrictive pattern remained significantly associated with an increase in risk for early 
respiratory failure (HR 1.84 95% CI 1.25-2.71, p < 0.002).  Under this definition of 
pulmonary restriction, subjects with and without still had significantly different 
cumulative incidence of early respiratory failure (p = 0.012, Figure 1C). 
Given the potential confounding effects of disease risk, we repeated these 
analyses after adjusting for disease risk in the models.  We also adjusted for year of 
transplantation to account for any changes in clinical practice over the duration of this 
study.  These adjustments reduced the point estimates.  However, the associations 
between pulmonary restriction and early respiratory failure remained statistically 
significant for the first two definitions, and a trend toward significance with a smaller 
effect size remained for the third definition (Table 4). 
Due to fundamental differences in patient characteristics among patients who 
receive a myeloablative versus a nonmyeloablative conditioning regimen, we also 
stratified the adjusted analysis based upon this criterion.  Among patients who received 
a myeloablative conditioning regimen (N = 2338), presence of pretransplant pulmonary 
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restriction remained significantly associated with increased risk for early respiratory 
failure in adjusted analysis (Definition 1: HR 1.67, 95% CI 1.43-1.95, p<0.001; Definition 
2: HR 1.68, 95% CI 1.43-1.96, p<0.001; Definition 3: HR 1.46, 95% CI 1.44-1.98, p < 
0.001). Among patients who received a reduced intensity conditioning regimen (N = 
207), the presence of pretransplant pulmonary restriction according to the first two 
definitions was associated with a higher risk for early respiratory failure.  This was no 
longer statistically significant in adjusted analyses (Definition 1: HR 2.81, 95% CI 0.73-
10.82, p = 0.134; Definition 2: HR 1.80, 95% CI 0.38-8.46, p = 0.455).  There were not 
enough cases with Definition 3 to perform an informative analysis. 
 
Pretransplant restrictive lung disease and nonrelapse mortality.  
Restrictive lung disease was also significantly associated with a higher risk for 
nonrelapse mortality (HR 2.41, 95% CI 1.98-2.94, p < 0.001, Table 5).  Sensitivity 
analyses using the two alternative definitions revealed that the association remained 
significant.  According to the second alternative definition, presence of a restrictive 
pattern was associated with a two-fold increase in risk for nonrelapse mortality (HR 
2.39, 95% CI 1.95-2.92, p < 0.001).  According to the third alternative criteria, presence 
of a restrictive pattern was still significantly associated with a two-fold increase in risk of 
nonrelapse mortality (HR 1.98 95% CI 1.57-2.50, p < 0.001).  Using each of these three 
criteria for pulmonary restriction, cumulative incidence of nonrelapse mortality was 
significantly different between subjects with and without pulmonary restriction (p < 
0.0001, Figure 1D, 1E and 1F). 
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We also repeated these analyses after adjusting for disease risk and year of 
transplant in the models.  The resultant point estimates decreased slightly, but the 
associations between pulmonary restriction and nonrelapse mortality remained 
statistically significant for all three definitions of pulmonary restriction (Table 4).  We 
also performed stratified analyses of the adjusted models based upon conditioning 
regimen.  Among patients who received a myeloablative conditioning regimen, presence 
of pretransplant pulmonary restriction remained significantly associated with increased 
risk for nonrelapse mortality (Definition 1: HR 2.07, 95% CI 1.68-2.56, p < 0.001; 
Definition 2: HR 2.10, 95% CI 1.70-2.60, p<0.001; Definition 3: HR 1.74, 95% CI 1.37-
2.22, p < 0.001).  Among patients who received a reduced intensity conditioning 
regimen, the association with nonrelapse mortality was neither consistent nor 
statistically significant with each definition for pretransplant pulmonary restriction 
(Definition 1: HR 1.69, 95% CI 0.86-3.32, p = 0.125; Definition 2: HR 1.18, 95% CI 0.55-
2.56, p = 0.669; Definition 3: HR 0.59, 95% CI 0.17-2.04, p = 0.404). 
 
DISCUSSION 
Evaluation of pulmonary function serves as an important method for risk 
stratification of patients who are considering allogeneic HCT [7, 8, 10, 23-25].  The most 
recent studies clearly indicate that the presence of poor lung function prior to stem cell 
transplantation is associated with worse outcomes, including respiratory failure and 
mortality [7, 24].  However, these studies, and many others, are limited in their ability to 
comment on the potential biologic reasons by which poor lung function might influence a 
patient’s post transplant clinical course.  There are two potential explanations for these 
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repeated observations in the literature.  First, impaired lung function likely leaves a 
patient with less pulmonary reserve, which means there is decreased lung capacity for 
surviving a period of critical illness.  Second, prior lung injury may have immunologically 
primed the lungs, predisposing the lungs to additional immunologic injury during the 
transplantation process.  However, based upon the observations of our current analysis, 
we suspect that there is a third explanation that may be linked to pulmonary restriction 
and respiratory muscle weakness. 
Pretransplant pulmonary restriction is a significant clinical problem.  In the current 
study, we found that the prevalence of pulmonary restriction among transplant 
candidates was only 8%, which is much lower than a previously reported observation of 
29% in a study of patients transplanted between 1984 and 1990, an entirely different 
era of stem cell transplantation [2, 12, 15].  Given the observations associated with our 
most stringent definition of pulmonary restriction, we suspect that the majority of these 
patients with pulmonary restriction (77%) likely had evidence of respiratory muscle 
weakness prior to transplantation.  This is supported by two observations.  First, there 
was a direct correlation between BMI and TLC values; patients with lower BMI, who 
may be more likely to be physiologically deconditioned due to poor nutritional status, 
had lower TLC measurements.  Second, there was also a significant relationship 
between disease type/risk and the degree of TLC reduction.  While this could indicate 
that patients with the most advanced disease were more likely to have had thoracic or 
pulmonary injury resulting in pulmonary restriction, patients who had radiographic 
evidence of parenchymal or thoracic abnormalities that could cause restrictive lung 
disease were in the minority.  Instead, we believe it is more likely that this group of 
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patients were most likely to be physiologically deconditioned due to multiple previous 
rounds of aggressive cancer treatment.  Based upon these observations, our results go 
beyond confirming that the presence of pulmonary restriction prior to transplantation 
was associated with a higher risk for respiratory failure and nonrelapse associated 
mortality.  Our study provides the first published evidence that pretransplant pulmonary 
restriction may be caused by respiratory muscle weakness.  This may partially explain 
the well-established relationship between poor lung function and worse allogeneic HCT 
outcomes. 
Our analysis accounted for the major variables that might influence pulmonary 
function.  First, as clearly demonstrated by the significant relationship between disease 
risk and pretransplant pulmonary restriction, we included disease risk as a potential 
confounding variable.  While this inclusion did attenuate the magnitude of the effect 
associated with pretransplant pulmonary restriction, we demonstrated that despite this 
adjustment, this relationship with the two outcomes remained statistically significant.  
Second, we also accounted for potential changes in patient selection over the course of 
this 14-year period by including the year of transplant in our models.  Again, this did not 
significantly influence our results, suggesting that this relationship is durable despite 
temporal changes related to transplant procedures and patient selection.  Third, 
recognizing the potential physiologic differences of patient populations receiving 
myeloablative versus reduced intensity conditioning regimens, we stratified our 
analyses accordingly and found that while the association remained strong among 
patients who received a myeloablative regimen, this was less so for those that received 
a reduced intensity regimen.  Nevertheless, we note that at least for the respiratory 
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failure endpoint, the point estimates for the reduced intensity patients were similar in 
magnitude to that observed among the myeloablative patients.  Our cohort may have 
been underpowered to demonstrate statistical significance for reduced intensity patients 
with respect to mortality. 
Our study is subject to the usual limitations associated with single center 
retrospective studies.  In addition, perhaps the most noteworthy limitation of our study is 
the lack of data from direct measurements of respiratory muscle strength with tools such 
as maximum inspiratory and expiratory pressures, or even indirectly with grip strength.  
We were only able to infer that a restrictive pattern noted on PFTs, in the absence of 
any radiographic features that may explain the restrictive pattern, was most likely 
attributable to respiratory muscle weakness.  However, respiratory muscle dysfunction 
is often present before pulmonary restriction is apparent on PFTs [26-28], suggesting 
that we have most likely underestimated the prevalence of respiratory muscle 
dysfunction.  Although data for respiratory muscle strength are not available in our 
database, we believe such measurements could contribute significantly to not only our 
understanding of this process, but also help to direct clinical care with interventions that 
can increase respiratory muscle strength.  In the future, prospective studies should 
consider incorporating relatively simple tools for measuring respiratory muscle function 
(e.g. maximum inspiratory and expiratory pressures), which are available through most 
pulmonary function testing laboratories, to evaluate patients with and without a 
pretransplant TLC <80%. 
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In summary, the results from the current study demonstrate that pretransplant 
restrictive lung disease was a risk factor for allogeneic HCT outcomes and that it may 
possibly be attributable to respiratory muscle weakness.  This may partially explain the 
higher risk for poor transplant outcome that has long been observed to be associated 
with poor pretransplant lung function.  If confirmed, future studies should consider 
evaluating interventions that strengthen respiratory muscles to determine whether such 
measures can improve the outcomes of allogeneic stem cell transplantation. 
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 Table 1. Patient pretransplant characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SD=standard deviation
Characteristic  n (%) or mean ± SD 
  
Total number of patients 2545 (100)  
Age at transplant 42 yrs. + 12.3 
Race (White) 2141 (84.1) 
Sex (males) 1487 (58.4) 
Donor type  
HLA-matched related 1690 (66.4) 
HLA-mismatched related 565 (22.2) 
Unrelated 237 (9.3) 
Conditioning regimens  
Myeloablative 2338 (92) 
Nonmyeloablative 207 (8) 
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Table 2. Distribution of pulmonary function parameters and chest imaging 
findings according to pretransplant total lung capacity categories 
 
 Pretransplant Total Lung Capacity Categories 
 ≥80% 70-79% 60-69% <60% p-value** 
Number of patients (%) 2351 (92.4) 134 (5.3) 39 (1.5) 21 (0.8)  
      
Mean body mass index (± SD) 27 ± 5 28 ± 6 26 ± 5 23 ± 4 0.010 
      
Mean percent of predicted (± SD)      
FEV1 94 ±13 74 ± 9 61 ± 11 53 ± 20 <0.0001 
FVC 100 ±13 75 ± 9 63 ± 12 55 ± 21 <0.0001 
FEV1/FVC ratio 0.77 ± 0.07 0.80 ± 0.05 0.80 ± 0.06 0.82 ± 0.07 <0.0001 
RV 100 ± 26 76 ± 17 76 ± 19 76 ±28 <0.0001 
DLCO 90 ±17 74 ±20 62 ±13 54 ±16 <0.0001 
      
Chest Radiographic Findings*      
Low probability NA 113 (76) 29 (19) 7 (5) <0.0001 
High probability NA 18 (46) 9 (23) 12 (31) <0.0001 
      
 
* Six patients did not have radiologic data available for review. 
** Pearson χ2 test and one-way analysis of variance were used to compare categorical and continuous 
variables, respectively  
SD=standard deviation; FEV1=forced expiratory volume in one second; FVC=forced vital capacity; 
RV=residual volume; DLCO =carbon monoxide diffusion capacity 
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Table 3.  Distribution of diagnosis, disease status, and disease risk according to 
pretransplant total lung capacity categories 
 
  Pretransplant TLC categories  
 Total ≥80% 
n (%) 
70-80% 
n (%) 
60-70% 
n (%) 
<60% 
n (%) 
p-value* 
       
Diagnosis      <0.001 
CML 810 770 (95) 30 (4) 8 (1) 2 (<1)  
ANL 747 695 (93) 39 (5) 10 (1) 3 (<1)  
MDS 446 410 (92) 24 (5) 9 (2) 3 (<1)  
ALL 261 230 (88) 21 (8) 7 (3) 3 (1)  
NHL 147 129 (88) 7 (5) 2 (1) 4 (3)  
MM 64 55 (86) 5 (8) 2 (8) 2 (3)  
CLL 50 46 (92) 3 (6) 0 (0) 1 (2)  
HD 25 15 (60) 6 (24) 1 (4) 3 (12)  
       
Disease status      <0.001 
Accelerated phase 139 132 (95) 5 (4) 1 (<1) 1 (<1)  
Blast crisis 92 80 (87) 8 (9) 3 (3) 1 (<1)  
Chronic phase 581 560 (96) 17 (3) 4 (<1) 0 (0)  
De novo 34 30 (88) 1 (2) 3 (10) 0 (0)  
Relapse 607 534 (88) 47 (8) 11 (2) 15 (2)  
Remission 591 555 (94) 27 (5) 8 (1) 1 (<1)  
Unknown 43 39 (91) 4 (9) 0 (0) 0 (0)  
Others  459 420 (92) 27 (6) 9(2) 3 (<1)  
       
Disease risk      <0.001 
Low 724 693 (96) 23 (3) 8 (1) 0 (0)  
Intermediate 995 926 (93) 50 (5) 15 (1) 4 (<1)  
High 808 715 (88) 61 (8) 15 (2) 17 (2)  
       
 
* Pearson χ2 test was used to compare categorical variables 
CML=chronic myelogenous leukemia; AML=acute myelogenous leukemia; MDS=myelodysplastic 
syndrome; ALL=acute lymphocytic leukemia; NHL=non-Hodgkins lymphoma; MM=multiple myeloma; 
CLL=chronic lymphocytic leukemia; HD=Hodgkin’s disease
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Table 4.  Sensitivity analysis of the association between pretransplant restriction 
and early respiratory failure. 
 
 
*Adjusted for disease risk and year 
TLC=total lung capacity; FEV1=forced expiratory volume in one second; FVC=forced vital capacity; 
HR=hazard ratio; CI=confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Unadjusted Adjusted* 
 N (%) Events HR (95% CI) p-value HR (95% CI) p-value 
TLC<80% 
No 
Yes 
 
2351 (92) 
194 (8) 
 
261 
43 
 
- 
2.22 (1.60 - 3.07) 
 
 
<0.001 
 
- 
1.90 (1.36 - 2.65) 
 
 
<0.001 
TLC<80%+FEV1/FVC 
>0.7 
No 
Yes 
 
 
2358  (93) 
185 (7) 
 
 
263 
41 
 
 
- 
2.19 (1.57 - 3.06) 
 
 
 
<0.001 
 
 
- 
1.90 (1.35 - 2.66) 
 
 
 
<0.001 
TLC<80%+FEV1/FVC
>0.7+low probability 
on chest imaging  
No 
Yes 
 
 
 
 
2396 (93) 
143 (6) 
 
 
 
 
275 
28 
 
 
 
 
- 
1.84 (1.25 - 2.71) 
 
 
 
 
 
0.002 
 
 
 
 
- 
1.59 (1.07 - 2.37) 
 
 
 
 
 
0.022 
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Table 5.  Sensitivity analysis of the association between pretransplant restriction 
and nonrelapse mortality. 
 
   Unadjusted Adjusted* 
 N (%) Events HR (95% CI) p-value HR (95% CI) p-value 
TLC<80% 
No 
Yes 
 
2351 (92) 
194 (8) 
 
261 
43 
 
- 
2.41 (1.98 - 2.94) 
 
 
<0.001 
 
- 
2.18 (1.79 - 2.65) 
 
 
<0.001 
TLC<80%+FEV1/FVC 
>0.7 
No 
Yes 
 
 
2358  (93) 
185 (7) 
 
 
263 
41 
 
 
- 
2.39 (1.95 - 2.92) 
 
 
 
<0.001 
 
 
- 
2.18 (1.78 - 2.66) 
 
 
 
<0.001 
TLC<80%+FEV1/FVC
>0.7+low probability 
on chest imaging  
No 
Yes 
 
 
 
 
2396 (93) 
143 (6) 
 
 
 
 
275 
28 
 
 
 
 
- 
1.98 (1.57 - 2.50) 
 
 
 
 
 
<0.001 
 
 
 
 
- 
1.82 (1.44 - 2.30) 
 
 
 
 
 
<0.001 
 
 
*Adjusted for disease risk and year 
TLC=total lung capacity; FEV1=forced expiratory volume in one second; FVC=forced vital capacity; 
HR=hazard ratio; CI=confidence interval 
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Figure 1. 
 
 
 
 
 
 
Figure 1.  Cumulative incidence curves for early respiratory failure (A, B, C) and 
nonrelapse mortality (E, F, G).  Dotted lines indicate patients with pretransplant 
pulmonary restriction, solid lines indicate patients without pretransplant pulmonary 
restriction.  Three definitions of pretransplant pulmonary restriction were used: 
TLC<80% alone (Figures A and D), TLC<80% and FEV1/FVC ratio >0.7 (Figures B and 
E), TLC<80%, FEV1/FVC ratio >0.7, and a low probability chest radiograph (Figures C 
and F). Gray’s test indicates significant differences between subjects with and without 
pulmonary restriction in cumulative incidence of early respiratory failure (A: p < 0.000, B: 
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p < 0.0001, C: p = 0.012) and cumulative incidence of nonrelapse mortality (D: p < 
0.0001, E: p < 0.0001, F: p < 0.0001). 
 
